AVONEX Solution for injection Ref.[9684]
Active ingredients: Interferon beta-1a

Source: European Medicines Agency (EU) |  Revision Year: 2019 |  Publisher: Biogen Netherlands B.V., Prins Mauritslaan 13, 1171 LP, Badhoevedorp, The Netherlands

Product name and form

AVONEX 30 micrograms/0.5 ml solution for injection.

Pharmaceutical Form

Solution for injection.

Clear and colourless solution.

Qualitative and quantitative composition

Each 0.5 ml pre-filled syringe contains 30 micrograms (6 million IU) of interferon beta-1a.

The concentration is 30 micrograms per 0.5 ml.

Using the World Health Organisation (WHO) International Standard for Interferon, 30 micrograms of AVONEX contain 6 million IU of antiviral activity. The activity against other standards is not known.

Excipient(s) with known effect: For the full list of excipients, see section 6.1.

Active Ingredient

Interferon beta-1a exerts its biological effects by binding to specific receptors on the surface of human cells. This binding initiates a complex cascade of intracellular events that leads to the expression of numerous interferon-induced gene products and markers. Whether the mechanism of action of interferon beta-1a in MS is mediated by the same pathway as the biological effects described above is not known because the pathophysiology of MS is not well established.

List of Excipients

Sodium acetate trihydrate
Acetic acid, glacial
Arginine hydrochloride
Polysorbate 20
Water for injections

Pack sizes and marketing

1 ml pre-filled syringe made of glass (Type I) with a tamper evident cap and plunger stopper (bromobutyl) containing 0.5 ml of solution.

Pack size: box of four or twelve pre-filled syringes of 0.5 ml. Each syringe is packed in a sealed plastic tray, which also contains one injection needle for intramuscular use.

Not all pack sizes may be marketed.

Marketing authorization holder

Biogen Netherlands B.V., Prins Mauritslaan 13, 1171 LP, Badhoevedorp, The Netherlands

Marketing authorization dates and numbers


Date of first authorisation: 13 March 1997
Date of latest renewal: 13 March 2007


Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Tunisia, Turkey, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.